Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
about
Current and emerging pharmacological treatments for sarcoidosis: a reviewLeflunomide: mode of action in the treatment of rheumatoid arthritisLactococcus lactis dihydroorotate dehydrogenase A mutants reveal important facets of the enzymatic functionRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisProtein instability and functional defects caused by mutations of dihydro-orotate dehydrogenase in Miller syndrome patientsDihydro-orotate dehydrogenase is physically associated with the respiratory complex and its loss leads to mitochondrial dysfunctionLeflunomide: a drug with a potential beyond rheumatologyTreatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazineDevelopment of oral immunomodulatory agents in the management of multiple sclerosisLeflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivoMethotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention.Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.Treating rheumatoid arthritis with new disease modifying drugs.Current and emerging strategies for the management of sarcoidosis.Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents.Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compoundsThe importance of mitochondrial DNA in aging and cancer.Oral disease-modifying therapies for multiple sclerosis.Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis.Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.Asthma refractory to glucocorticoids: the role of newer immunosuppressants.Rational Design of Benzylidenehydrazinyl-Substituted Thiazole Derivatives as Potent Inhibitors of Human Dihydroorotate Dehydrogenase with in Vivo Anti-arthritic Activity.Leflunomide: long-term clinical experience and new uses.Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing.Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine.Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 yearsLeflunomide-related lung injury in patients with rheumatoid arthritis: imaging features.Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells.An update of teriflunomide for treatment of multiple sclerosis.Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis.Teriflunomide and its mechanism of action in multiple sclerosis.Pathophysiology of multiple sclerosis and the place of teriflunomide.Drugs in development for relapsing multiple sclerosis.Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.Teriflunomide: a review of its use in relapsing multiple sclerosis.Leflunomide: an immunosuppressive drug with multiple effects on T cell function.
P2860
Q24633717-D49C95CA-2093-4DBA-98E0-7F5D87280BBDQ24675005-95F9E201-5ED9-423D-B90B-689AC5B27358Q27641154-73F58CAA-DE00-45F9-B438-ABABFAC21F5CQ28087414-4EDC15AE-824F-4A5B-997C-25E4FE0A2AF0Q28274852-7510F24E-AA03-4F78-BBF7-D5EBBBC634BBQ28280768-B3F198AD-692A-48B4-B80F-7671D4C35C41Q28294236-D15E48B4-08A2-41FE-9688-F9415932F3AEQ28353468-92C3AE05-03F1-48A2-A834-ED1A8F247F9DQ28388704-38BD31E5-FD09-4FD9-B656-7069C56382F1Q28535313-33DBF42E-E3CF-4E5F-9A28-5D3D845A610DQ33869850-AB761C95-3ECF-4F96-9A81-6941BC54E1B0Q33903812-036ECD88-0EED-433C-9BBB-DD696D07B07FQ33918869-C6BA3208-2DE8-4C40-88F3-2BA02A333B38Q34389332-5CAA8814-08DC-4C73-B53B-54B8913036D9Q34417518-6D371CB6-B7D9-49D9-885C-27C0BC909686Q34567932-9FEB3689-E298-43C8-8093-D4FD01CF5F0AQ34636680-E91AC6DD-29C6-434C-8A17-E3E2CAAD55C3Q34714866-634C65A9-419A-41F2-8233-DEACAE26B4F7Q34760255-B2DFEE2B-B09C-4B31-91EA-730D7B1F8752Q34974582-90FF3666-3C3C-4821-8649-6251EA242D47Q34996562-9BF417C1-8C0F-49D9-9EC9-2E2E041CF1FBQ35092909-476270C8-705C-4B7A-B22F-83B646ECC09FQ35105760-A10FC02C-A1E6-4108-9796-BC57D4D357D5Q35627919-6D42A40B-07B1-430E-85A4-A44E76CE77C5Q36129211-08C4AAA1-4ADA-46DC-90B5-4FE3C95AB30DQ36150789-6E77BC29-FBBE-4F6C-BCB6-AFEEA3CE38FAQ36289418-7CE031E3-20E5-48D5-A917-F3477C4ADD5EQ36482233-ACCBDAA3-9C0E-4090-BB44-8F84D35299F9Q36613420-B4B32190-0A28-46C9-937C-2B70C91140CDQ36618003-704057D6-B9CE-4B88-ABD1-5EB24B5D2E00Q36733029-006902DB-EBD0-4F02-9491-A70BBCCDB2AFQ36906008-AC9125C4-C675-4DCB-A9E8-F606DB289E63Q37358239-B1547DC7-A35F-4E05-97B2-A1948B722C4FQ37730005-288D23C8-9853-49FC-BE5E-78C4456C6DDEQ37794267-F052D78A-6801-461D-88DB-BB6DD00534A8Q38101004-EC14A71D-B922-45A4-AF58-D7BC93D1A17AQ38107524-EA00ABE0-71E3-4AC4-9EC2-0D3E7E9EBCF9Q38117110-53DB7A0C-806A-4B64-808C-89BD00CE9B56Q38160410-A36017E1-FDF2-4474-A180-5E9BA80FBE7BQ38175431-6F70A05C-0081-4E29-A8B5-10700565B87E
P2860
Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Leflunomide inhibits pyrimidin ...... mphocytes from healthy humans.
@en
Leflunomide inhibits pyrimidin ...... mphocytes from healthy humans.
@nl
type
label
Leflunomide inhibits pyrimidin ...... mphocytes from healthy humans.
@en
Leflunomide inhibits pyrimidin ...... mphocytes from healthy humans.
@nl
prefLabel
Leflunomide inhibits pyrimidin ...... mphocytes from healthy humans.
@en
Leflunomide inhibits pyrimidin ...... mphocytes from healthy humans.
@nl
P2093
P2860
P356
P1476
Leflunomide inhibits pyrimidin ...... mphocytes from healthy humans.
@en
P2093
Fairbanks LD
Kirschbaum B
Richards DF
Rückemann K
Simmonds HA
P2860
P304
21682-21691
P356
10.1074/JBC.273.34.21682
P407
P577
1998-08-01T00:00:00Z